The Impact of Lagged R&D Expenses on Firm Performance: Empirical Evidence from the BSE Healthcare Index

Show simple item record

dc.contributor.author Sinha, Abhijit
dc.contributor.author Mondal, Keyarani
dc.date.accessioned 2021-01-11T04:44:42Z
dc.date.available 2021-01-11T04:44:42Z
dc.date.issued 2021-12
dc.identifier.issn 2579-2210
dc.identifier.issn 1800-363x
dc.identifier.uri http://220.247.247.85:8081/handle/123456789/36832
dc.description.abstract The study finds the impact of lagged Research and Development expenditure on financial performance. The investigation analyses 69 pharmaceutical companies included in the BSE healthcare index (India) using secondary data for the period of 2008 to 2017. The two dependent variables which are considered separately are Return on Asset (ROA) and Return on Equity (ROE). The two estimated regression models show that both the lagged value and its quadratic term have a significant influence on the accounting-based measures. With regard to the control variables, size and leverage are found to influence negatively whereas liquidity poses a positive effect on these two accounting-based performance measures. The article contributes by highlighting that the true relationship between R&D and financial performance is represented by a U-shaped curve as evident in few other studies. en_US
dc.language.iso other en_US
dc.publisher Faculty of Management & Finance, University of Colombo en_US
dc.relation.ispartofseries Volume. 11;No. 02
dc.subject Lagged R&D en_US
dc.subject Firm Performance en_US
dc.subject ROA en_US
dc.subject ROE en_US
dc.subject BSE Healthcare Index en_US
dc.title The Impact of Lagged R&D Expenses on Firm Performance: Empirical Evidence from the BSE Healthcare Index en_US
dc.type Article en_US
dc.identifier.accno 45742 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search


Browse

My Account